Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986263 in compensated cirrhosis due to NASH
NL-OMON53971Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ND-L02-s0201 in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of participants with at least 1-stage improvement in liver fibrosis by NASH CRN fibrosis score. Planned start Aug 2022; status: withdrawn.
02
Drugs
ND-L02-s0201
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on NL-OMON53971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53971.